15 recruiting, 9 unknown, 7 completed, 2 withdrawn. 12 Phase 2, 10 Not applicable, 8 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 11, Unknown 1 |
| Not applicable | 10 | Completed 3, Unknown 3, Recruiting 2, Withdrawn 2 |
| Phase 3 | 8 | Recruiting 8 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
Follow Haematological Malignancy: new trials by email Literature Review of Haematological Malignancy trials Research Report on Haematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial genotype-directed dosing with dosing software based on therapeutic drug monitoring - Fungal Infection, Haematological Malignancy | Phase 2 | Recruiting | The University of Queensland | 104 | 2025-04-14 | 2026-04-16 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| Seen and Be Heard: Ensuring Fair Cancer Care for All Children Cancer, Oncology | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 50 | 2024-09-02 | 2024-07-01 | |
| Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation Detection of donor-specific anti-HLA antibody (DSA) - Haematological Malignancy | Completed | Peking University People's Hospital | 314 | 2024-01-01 | 2026-01-02 | |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia Haematological Malignancy, Febrile Neutropenia | Active not recruiting | Hospital Universitari de Bellvitge | 228 | 2023-10-27 | 2025-01-22 | |
| Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital Home patient management, Hospital patient management - Haematological Malignancy | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2023-05-11 | 2025-02-07 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation Traditional Control, Oral Nutritional Supplement - Haematological Malignancy | Not applicable | Completed | RenJi Hospital | 100 | 2022-08-01 | 2026-05-11 |
| Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy 6 sessions of adapted physical activity after stem cell transplant - Haematological Malignancy | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 75 | 2022-06-10 | 2024-01-30 |
| Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation Physical activity program - Haematological Malignancy, Acute Leukemia | Not applicable | Completed | Centre Leon Berard | 15 | 2022-05-25 | 2024-08-21 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2024-07-15 |
| Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies TempTraq temperature monitor - Haematological Malignancy, Leukemia | Unknown | Malaghan Institute of Medical Research | 20 | 2021-11-18 | 2022-01-24 | |
| oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort Graft Vs Host Disease, Haematological Malignancy | Recruiting | The University of Hong Kong | 500 | 2021-04-30 | 2021-12-27 |
Showing 20 of 36. Sign in to see all of them.
Hematologic Neoplasms (36) · Neoplasms (14) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Glioma (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Multiple Myeloma (4) · Colorectal Neoplasms (3) · Leukemia (3) · Ovarian Neoplasms (3) · Anemia, Aplastic (2) · Carcinoma, Non-Small-Cell Lung (2) · Erdheim-Chester Disease (2) · Febrile Neutropenia (2)
Hemic and Lymphatic Diseases (36) · Hematologic Diseases (35) · Neoplasms by Site (30) · Neoplasms (22) · Immune System Diseases (13) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (6) · Blood Protein Disorders (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5)
Vemurafenib (3) · alectinib (3) · cobimetinib (3) · dabrafenib (3) · entrectinib (3) · trametinib (3) · Trastuzumab (2) · atezolizumab (2) · capmatinib (2) · pertuzumab (2) · Amoxicillin (1) · Azacitidine (1) · Blood Specimen Collection (1) · Bortezomib (1) · CCS1477 (1)
Cancer Research UK (7) · Centre Leon Berard (2) · Melbourne Health (2) · Nottingham University Hospitals NHS Trust (2) · Assistance Publique - Hôpitaux de Paris (1) · CellCentric Ltd. (1) · Centre Henri Becquerel (1) · Centre Hospitalier Universitaire de Nice (1) · General Hospital Groeninge (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Helsinki University Central Hospital (1) · Hospital Universitari de Bellvitge (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Malaghan Institute of Medical Research (1)
United Kingdom (12) · France (6) · Australia (4) · Italy (3) · China (2) · Spain (2) · United States (2) · Belgium (1) · Denmark (1) · Finland (1) · Hong Kong (1) · Malaysia (1) · New Zealand (1) · Sweden (1) · Switzerland (1)
Matthew Krebs, Dr (6) · Alessandro Lucchesi, MD (1) · Allie Lee (1) · Brieuc Cherel, MD (1) · Carlota Gudiol, Professor, MD, PhD (1) · Claude Preudhomme, Professor (1) · David Ritchie, FRACP, PhD (1) · Fabio Frediani, MD (1) · Fabrice Jardin, Professor (1) · Giovanni Martinelli, Prof (1) · Jason A Roberts, PhD (1) · John Radford (1) · Katriina Jalkanen, MD, PhD (1)
PMID 21532851, PMID 21542449, PMID 21622762, PMID 22106690, PMID 22373458, PMID 23244672, PMID 25909835, PMID 28912923, PMID 40499967, PMID 41001994, PMID 41123648, PMID 41259352, PMID 41808418, PMID 4305950
2017 (1)